Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
What Does MMP9 Antibody Detection Show?
2026-11-20
MMP9 antibody signals can reveal immunoreactive protein abundance or distribution, but they do not independently measure catalytic activity, extracellular-matrix degradation, leukocyte movement, or bone resorption. Interpretation depends on the assay readout and the biological level being measured.
Multiplex CRISPR: What the Evidence Shows
2026-11-20
A 2025 review presents multiplex CRISPR as a versatile framework for simultaneous gene perturbation, structural-variant modeling, epigenome control and context-dependent cell killing. The strongest evidence supports feasibility across cellular systems, while delivery, off-target activity, repair variability and translation remain important limits.
CSN2 Targeting and High-Yield Rabbit Pharming
2026-11-19
A literature-focused analysis of how endogenous CSN2 regulation, targeted integration and allele transmission were linked to high tdTomato concentrations in rabbit milk, with emphasis on evidence strength, comparators and limits to generalization.
What Does Ketone Ester Show About Seizure Delay?
2026-11-19
Ketone Ester is documented as a ketone-body–elevating compound associated with altered glucose, insulin, leptin, and seizure-latency measurements in rats exposed to hyperbaric oxygen. The evidence supports a metabolic association with CNS oxygen toxicity research, but it does not establish which change causes seizure delay or whether the finding extends beyond the reported animal model.
How LNPs Shape p53 mRNA Evidence
2026-11-18
Lipid nanoparticles can protect mRNA, promote cellular uptake and support endosomal escape, but those delivery functions do not by themselves establish p53 restoration, tumor selectivity or clinical benefit. The current evidence is strongest for the platform-level mechanism and remains more indirect for p53-specific therapeutic conclusions.
Why Cytosolic crRNAs Improve Cas13 Activity
2026-11-18
A literature-focused analysis of how U1 promoter-driven CRISPR RNAs alter intracellular localization and improve RNA knockdown, editing, translational repression, and miRNA-related regulation in Cas13 systems.
What Can the USP2 Catalytic Domain Show?
2026-11-17
A recombinant USP2 catalytic domain can provide evidence for substrate-level ubiquitin editing, but that biochemical readout should not be treated as direct proof of isoform-specific effects in cells, tumors, apoptosis, or circadian regulation.
When Context Changes a High-Yield Result
2026-11-17
A reported 15–20 g/L milk yield in targeted rabbit lines is persuasive evidence for a CSN2-locus proof of concept, but its meaning depends on the reporter, comparator, inheritance data, and measurement context. HEPES and pH-buffer claims belong to a separate evidence layer, not to the genetic explanation of this result.
Why Cytosolic crRNAs Improve Cas13 RNA Control
2026-11-16
A 2025 study shows that changing crRNA transcription and processing can shift Cas13 activity toward the cytoplasm, improving reported RNA knockdown, editing, translational repression, and miRNA-related assays. The strongest conclusion is mechanistic: subcellular guide-RNA localization is a major determinant of RNA-targeting performance, although the available evidence remains largely cell-based and assay-specific.
How Malachite Green Reports Free Phosphate
2026-11-16
A malachite green phosphate assay measures free inorganic phosphate through formation of a colored phosphomolybdate species. That chemical readout can support biochemical phosphate quantification and interpretation of ATPase activity assays, but it is not a direct measurement of enzyme catalysis or phosphate still bound to proteins and lipids.
What Does Indoximod Evidence Actually Show?
2026-11-15
Indoximod, also known as NLG-8189, is best interpreted as an IDO-pathway immunology hypothesis rather than as a single proof of anticancer efficacy. The documented evidence connects tryptophan metabolism, regulatory T-cell behavior, combination-treatment responses in mouse models, and early clinical tolerability, but each layer answers a different research question.
What Does a Doripenem Readout Measure?
2026-11-14
Doripenem-associated growth or viability signals are downstream consequences of altered bacterial cell-wall assembly, not direct measurements of penicillin-binding-protein engagement. Separating molecular action, envelope damage, population change and assay signal helps define what a result can—and cannot—show.
What Can Ipriflavone Show in Bone Research?
2026-11-13
Ipriflavone is documented as a synthetic isoflavone derivative associated with inhibition of bone resorption. The useful research question is how that phenotype should be separated from chemical identity, molecular mechanism, cellular readouts, and clinical relevance.
How 6,7-DHB Signals CYP3A4 Inhibition
2026-11-13
6,7-Dihydroxy Bergamottin provides a functional way to interpret CYP3A4 inhibition across purified-enzyme, microsomal, recombinant-membrane, and cell-based models. The comparison clarifies what the reported 25 μM IC50 and substrate-metabolism findings show—and why they do not, by themselves, establish a clinical drug interaction or a complete molecular mechanism.
How Might LB-100 Sensitize Tumors?
2026-11-12
LB-100 is described as a protein phosphatase 2A inhibitor whose reported cellular, drug-accumulation, and xenograft findings support a hypothesis linking PP2A signaling to chemotherapy response, while leaving the causal mechanism and clinical relevance unresolved.